Brad Margus, chief executive of drug-discovery company Cerevance, said that lowering drug prices will especially hurt companies working on the hardest-to-crack diseases, where even though a drug that works would have a huge market, it’s nearly impossible to persuade investors to support new approaches. “The price controls now being pushed threaten to remove the chance for my investors to get those returns,” he said.

Celyad is focusing on advancing chimeric antigen receptor T cell (CAR T) therapies. “Approved cell therapy products have a very, very high response rate,” he said. “The challenge is in expanding that therapy from hematologic malignancies to other targets – in particular, to solid tumors – where we, as a field, haven’t yet cracked the code.”

Dale Christensen is the Director of Clinical Development at TFF Pharmaceuticals. It’s an Austin-based company and specializes in “Thin Film Freezing”—a technology first created at UT Austin.

Elicio Therapeutics’ lymph node-targeting vaccine displayed cellular and humoral immunity to SARS-CoV-2 in a pre-clinical study.

Scynexis is introducing Brexafemme (ibrexafungerp tablets), the first and only oral non-azole prescription medication approved by the Food and Drug Administration to treat vulvovaginal candidiasis, commonly referred to as vaginal yeast infection.

In an interview with PharmaShots, James E. Brown, President, CEO, and Director of Durect shared his views on the clinical data of DUR-928 in P-1b trial for NASH and P-I trial for Hepatic Impairment

In an interview with PharmaShots, James Graham, CEO of Recce Pharmaceuticals shared his views on the multiple patient dosing in P-I/II clinical trial of RECCE 327 (R327) for the treatment of infected burn wounds.